Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells

Breast Cancer Research and Treatment

Volumn 135, Issue 2, 2012, Pages 433-444

  Fiskus, Warren ^a   Hembruff, Stacey L ^a   Rao, Rekha ^a   Sharma, Priyanka ^a   Balusu, Ramesh ^a   Venkannagari, Sreedhar ^a   Smith, Jacqueline E ^a   Peth, Karissa ^a   Peiper, Stephen C ^b   Bhalla, Kapil N ^a  

^a UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Aurora kinase inhibitor; Hsp90; Survivin; Triple negative breast cancer; Vorinostat

Indexed keywords

ALISERTIB; AURORA A KINASE; AURORA B KINASE; AURORA C KINASE; AURORA KINASE INHIBITOR; DNA 26S; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HEAT SHOCK PROTEIN 90; PROGESTERONE RECEPTOR; RAF PROTEIN; SURVIVIN; TOZASERTIB; VORINOSTAT;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHROMOSOME 20; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MITOSIS; MITOSIS SPINDLE; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; GENE DOSAGE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYDROXAMIC ACIDS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, INBRED NOD; MICE, SCID; PIPERAZINES; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866528749     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2171-9     Document Type: Article

References (40)

1. Mountzios G, Terpos E, Dimopoulos MA (2008) Aurora kinases as targets for cancer therapy. Cancer Treat Rev 34:175-182 (Pubitemid 351372885)
2. Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W (2010) Aurora kinases inhibitors-rising stars in cancer therapeutics? Mol Cancer Ther 9:268-278
3. Fu J, Bian M, Jiang Q, Zhang C (2007) Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 5:1-10
4. Marumoto T, Zhang D, Saya H (2005) Aurora-A-a guardian of poles. Nat Rev Cancer 5:42-50 (Pubitemid 40052324)
5. Fukushige S, Waldman FM, Kimura M, Abe T, Furukawa T, Sunamura M et al (1997) Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Genes Chromosomes Cancer 19:161-169 (Pubitemid 27278803)
6. Nishida N, Nagasaka T, Kashiwagi K, Boland CR, Goel A (2007) High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers. Cancer Biol Ther 6:525-533 (Pubitemid 47328326)
7. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A et al (1998) Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20:189-193 (Pubitemid 28455454)
8. Wang X, Zhou YX, Qiao W, Tominaga Y, Ouchi M, Ouchi T et al (2006) Overexpression of Aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 25:7148-7158 (Pubitemid 44764184)
9. Hontz AE, Li SA, Lingle WL, Negron V, Bruzek A, Salisbury JL et al (2007) Aurora A and Aurora B overexpression and centrosome amplification in early estrogen-induced tumor foci in the Syrian hamster kidney: implications for chromosomal instability, aneuploidy and neoplasia. Cancer Res 67:2957-2963 (Pubitemid 46724831)
10. Finetti P, Cervera N, Charafe-Jauffret E, Chabannon C, Charpin C, Chaffanet M et al (2008) Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. Cancer Res 68:767-776 (Pubitemid 351206753)
11. Kollareddy M, Zheleva D, Dzubak P, Brahmkshatriya PS, Lepsik M, Hajduch M (2012) Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs. doi:10.1007/s10637-012-9798-6
12. Schmit TL, Ahmad N (2007) Regulation of mitosis via mitotic kinases: new opportunities for cancer management. Mol Cancer Ther 6:1920-1931 (Pubitemid 47052482)
13. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T et al (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10:262-267 (Pubitemid 38667616)
14. Tyler RK, Shpiro N, Marquez R, Eyers PA (2007) VX-680 inhibits Aurora A and Aurora B kinase activity in human cells. Cell Cycle 6:2846-2854 (Pubitemid 350277179)
15. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI (2006) The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 66:7668-7677 (Pubitemid 44289225)
16. Richon VM (2006) Cancer biology: mechanism of antitumor action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer 95:S2-S6 (Pubitemid 44950782)
17. Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM et al (2009) Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2:31
18. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N et al (2008) Determination of the class and isoform selectivity of small-molecule histone deactylase inhibitors. Biochem J 409:581-589 (Pubitemid 351184977)
19. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51 (Pubitemid 43054973)
20. Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H et al (2003) Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine and epothilone B. Mol Cancer Ther 10:971-984
21. Fiskus W, Ren Y, Mohapatra A, Bali P, Mandawat A, Rao R et al (2007) Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res 13:4882-4890 (Pubitemid 47294796)
22. Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M et al (2005) Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of Her-2. Clin Cancer Res 11:6382-6389 (Pubitemid 41262970)
23. Stevens FE, Beamish H, Warrener R, Gabrielli B (2008) Histone deacetylase inhibitors induce mitotic slippage. Oncogene 27: 1345-1354 (Pubitemid 351317466)
24. Li Y, Kao GD, Garcia BA, Shabanowitz J, Hunt DF, Qin J et al (2006) A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. Genes Dev 20:2566-2579 (Pubitemid 44396841)
25. Yang Y, Rao R, Shen J, Tang Y, Fiskus W, Nechtman J et al (2008) Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res 68:4833-4842
26. Park JH, Jong HS, Kim SG, Jung Y, Lee KW, Lee JH et al (2008) Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. J Mol Med 86: 117-128
27. Fiskus W, Wang Y, Joshi R, Rao R, Yang Y, Chen J et al (2008) Co-treatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res 14:6106-6115
28. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C et al (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylases, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60:5165-5170
29. Cohen LA, Marks PA, Rifkind RA, Amin S, Desai D, Pittman B et al (2002) Suberoylanalide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogeninduced mammary tumors. Anticancer Res 22:1497-1504 (Pubitemid 34839156)
30. Kelly WK, O' Connor OA, Krug LM, Chiao JH, Heaney M, Curley T (2005) Phase I study of an oral histone deacetylase inhibitor in patients with advanced cancer. J Clin Oncol 23:3923-3931 (Pubitemid 46218695)
31. Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V et al (2011) Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 29:1198-1203
32. Pal SK, Childs BH, Pegram M (2011) Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 125: 627-636
33. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple negative breast cancer. New Engl J Med 363:1938-1948
34. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
35. Rao R, Nalluri S, Kolhe R, Yang Y, Fiskus W, Chen J et al (2010) Treatment with panobinostat induces glucose regulated protein 78 (GRP78) acetylation and endoplasmic reticulum stress in breast cancer cells. Mol Cancer Ther 9:942-952
36. Fiskus W, Wang Y, Sreekumar A, Buckley K, Shi H, Jillella A et al (2009) Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114:2733-2743
37. Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W et al (2007) Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci USA 104:4106-4111 (Pubitemid 47181586)
38. Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C et al (2007) AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 13:3682-3688 (Pubitemid 46955132)
39. Ramaswamy B, Bhalla K, Cohen B, Pelligrino C, Hershman D, Chuang E, et al (2009) Phase I-II study of the histone deacetylase inhibitor vorinostat plus paclitaxel and bevacizumab in patients with metastatic breast cancer: New York Cancer Consortium trial P7703. Proc Am Assoc Cancer Res. Apr 18-22, Denver CO, Philadelphia, AACR; 2009: Abstract 3571
40. Ramaswamy B, Fiskus W, Cohen B, Pellegrino C, Hershman DL, Chuang E et al (2012) Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Res Treat 132:1063-1072